Loading…
Targeting the Fas/FasL system in Rheumatoid Arthritis therapy: Promising or risky?
•Apoptotic pathways, particularly the ones involving Fas/FasL, are defective in RA.•The Fas-FasL system may instead have a proinflammatory effect in RA.•sFasL blocks mFasL-mediated apoptosis, but also activates RA FLS. Rheumatoid Arthritis (RA) is a chronic inflammatory disease affecting synovial jo...
Saved in:
Published in: | Cytokine (Philadelphia, Pa.) Pa.), 2015-10, Vol.75 (2), p.228-233 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •Apoptotic pathways, particularly the ones involving Fas/FasL, are defective in RA.•The Fas-FasL system may instead have a proinflammatory effect in RA.•sFasL blocks mFasL-mediated apoptosis, but also activates RA FLS.
Rheumatoid Arthritis (RA) is a chronic inflammatory disease affecting synovial joints. Tumor necrosis factor (TNF) α is a key component of RA pathogenesis and blocking this cytokine is the most common strategy to treat the disease. Though TNFα blockers are very efficient, one third of the RA patients are unresponsive or present side effects. Therefore, the development of novel therapeutic approaches is required. RA pathogenesis is characterized by the hyperplasia of the synovium, closely associated to the pseudo-tumoral expansion of fibroblast-like synoviocytes (FLS), which invade and destroy the joint structure. Hence, depletion of RA FLS has been proposed as an alternative therapeutic strategy. The TNF family member Fas ligand (FasL) was reported to trigger apoptosis in FLS of arthritic joints by binding to its receptor Fas and therefore suggested as a promising candidate for targeting the hyperplastic synovial tissue. However, this cytokine is pleiotropic and recent data from the literature indicate that Fas activation might have a disease-promoting role in RA by promoting cell proliferation. Therefore, a FasL-based therapy for RA requires careful evaluation before being applied. In this review we aim to overview what is known about the apoptotic and non-apoptotic effects of Fas/FasL system and discuss its relevance in RA. |
---|---|
ISSN: | 1043-4666 1096-0023 |
DOI: | 10.1016/j.cyto.2014.10.004 |